{"disease":{"id":"artery","name":"artery"},"drugs":{"marketed":[{"drug_id":"atorvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"atorvastatin","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA reductase inhibitor (statin)","quality_score":77,"revenue":"1000.0","mechanism":"Selective competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis."},{"drug_id":"inositol","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Inosital","generic_name":"INOSITOL","company_name":"","drug_phase":"discontinued","molecular_target":"","drug_class":"inositol","quality_score":null,"revenue":null,"mechanism":"Inosital works by influencing the metabolism of lipids in the body."},{"drug_id":"xarelto","indication_name":"Prevention of atherothrombotic events in symptomatic peripheral artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Xarelto","company_name":"University Hospital, Montpellier","drug_phase":"marketed","molecular_target":"Suppressor of tumorigenicity 14 protein, Coagulation factor X, Coagulation factor X","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fludeoxyglucose","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"fludeoxyglucose","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"FLUDEOXYGLUCOSE","company_name":"Downstate Clincl","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive sugar molecule that accumulates in cells with high metabolic activity, allowing for visualization of cancer and other conditions."},{"drug_id":"f-18","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"f-18","indication_name":"coronary artery disease and left ventricular dysfunction","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fludeoxyglucose F-18","generic_name":"F-18","company_name":"3D Imaging Drug","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Fludeoxyglucose F-18 is a radioactive molecule that accumulates in areas of high metabolic activity, allowing for imaging of various conditions."},{"drug_id":"fluvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lescol","generic_name":"FLUVASTATIN","company_name":"Novartis","drug_phase":"marketed","molecular_target":"HMG-CoA reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Fluvastatin sodium inhibits HMG-CoA reductase, reducing cholesterol biosynthesis and increasing LDL receptor activity, lowering plasma cholesterol."},{"drug_id":"rivaroxaban","indication_name":"Prevention of atherothrombotic events in symptomatic peripheral artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xarelto","generic_name":"rivaroxaban","company_name":"Johnson & Johnson","drug_phase":"marketed","molecular_target":"Factor Xa (FXa)","drug_class":"Direct Factor Xa Inhibitor","quality_score":71,"revenue":null,"mechanism":"Selective FXa inhibitor that decreases thrombin generation without requiring cofactors."},{"drug_id":"alprostadil","indication_name":"Pulmonary artery stenosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caverject","generic_name":"ALPROSTADIL","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Prostaglandin E2 receptor EP3 subtype","drug_class":"Prostaglandin Analog [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"oral-p2y12-receptor-blocker","indication_name":"Reduction of thrombotic cardiovascular events in patients with atherosclerotic disease, including those with a recent ischemic stroke or peripheral artery disease (PAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Oral P2Y12 receptor blocker","company_name":"Italian Society of Invasive Cardiology","drug_phase":"marketed","molecular_target":"P2Y12 adenosine diphosphate receptor on platelet surface","drug_class":"Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"non-interventional-study","indication_name":"Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Non-Interventional Study","generic_name":"non-interventional-study","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase","drug_class":"Anticoagulant","quality_score":25,"revenue":null,"mechanism":""},{"drug_id":"simvastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zocor","generic_name":"simvastatin","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Nuclear receptor subfamily 1 group I member 3, Nuclear receptor subfamily 4 group A member 2, 3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor [EPC]","quality_score":40,"revenue":null,"mechanism":null},{"drug_id":"telmisartan","indication_name":"History of myocardial infarction due to atherothrombotic coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Micardis","generic_name":"TELMISARTAN","company_name":"Boehringer Ingelheim","drug_phase":"marketed","molecular_target":"Type-2 angiotensin II receptor","drug_class":"Angiotensin 2 Receptor Blocker [EPC]","quality_score":10,"revenue":null,"mechanism":"Micardis works by blocking the action of angiotensin II, a hormone that constricts blood vessels and increases blood pressure."},{"drug_id":"nitroglycerin","indication_name":"Acute relief of angina pectoris due to coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"myoinositol","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Myoinositol","company_name":"University of Colorado, Denver","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"lipitor","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lipitor","generic_name":"Atorvastatin Calcium","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"atorvastatin","quality_score":10,"revenue":null,"mechanism":"Lipitor is a selective, competitive inhibitor of HMG-CoA reductase, a key enzyme in cholesterol synthesis."},{"drug_id":"technetium","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Technetium Tc 99M Sestamibi","generic_name":"TECHNETIUM","company_name":"Cyclomedica","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue similar to thallous chloride TI-201, with possible mitochondrial retention."},{"drug_id":"technetium","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Technetium Tc 99M Sestamibi","generic_name":"TECHNETIUM","company_name":"Cyclomedica","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":44,"revenue":null,"mechanism":"Technetium Tc 99m Sestamibi accumulates in viable myocardial tissue similar to thallous chloride TI-201, with possible mitochondrial retention."},{"drug_id":"flurpiridaz","indication_name":"coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Flyrcado","generic_name":"FLURPIRIDAZ","company_name":"Ge Hlthcare","drug_phase":"marketed","molecular_target":"","drug_class":"Radioactive Diagnostic Agent [EPC]","quality_score":55,"revenue":null,"mechanism":"Flyrcado emits radiation to create detailed images of the heart, allowing for the diagnosis of coronary artery disease and other heart conditions."},{"drug_id":"ppsv23","indication_name":"Prevention of invasive disease caused by Streptococcus pneumoniae in adults 2 years of age or older with chronic heart disease, including congestive heart failure, coronary artery disease, or cardiac transplantation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ppsv23","generic_name":"ppsv23","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Streptococcus pneumoniae","drug_class":"Vaccine","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"lovastatin","indication_name":"Slow Progression of Coronary Artery Disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mevacor","generic_name":"LOVASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"3-hydroxy-3-methylglutaryl-coenzyme A reductase","drug_class":"HMG-CoA Reductase Inhibitor","quality_score":null,"revenue":null,"mechanism":"Mevacor works by inhibiting the enzyme HMG-CoA reductase, which plays a key role in cholesterol production in the liver."},{"drug_id":"pritor","indication_name":"History of myocardial infarction due to atherothrombotic coronary artery disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Pritor","company_name":"DongKoo Bio & Pharma","drug_phase":"phase_1","molecular_target":"ATP-binding cassette sub-family G member 2, Multidrug and toxin extrusion protein 1, Type-2 angiotensin II receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"prostavasin","indication_name":"Pulmonary artery stenosis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Prostavasin","company_name":"Hannover Medical School","drug_phase":"phase_2","molecular_target":"Cation channel sperm-associated protein 1, Cation channel sperm-associated protein 2, Cation channel sperm-associated protein 3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"caduet","indication_name":"Coronary Artery Disease (CAD)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Caduet","generic_name":"Amlodipine Besylate","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"L-type calcium channel","drug_class":"Dihydropyridine calcium channel blocker","quality_score":76,"revenue":null,"mechanism":"Calcium channel antagonist inhibiting transmembrane calcium influx into vascular and cardiac muscle."}],"pipeline":[{"drug_id":"nitroglycerin","indication_name":"Effect of topically-applied milrinone or nitroglycerin on internal mammary artery free flow","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"NITROGLYCERIN","company_name":"","drug_phase":"marketed","molecular_target":"Nitric oxide synthase pathway","drug_class":"Nitrate Vasodilator [EPC]","quality_score":10,"revenue":null,"mechanism":"Nitroglycerin forms nitric oxide, which activates guanylate cyclase, leading to increased cyclic GMP and subsequent vasodilation in smooth muscle."},{"drug_id":"phytonadione","indication_name":"Coronary artery calcification in hemodialysis patients","indication_type":"pipeline","phase":"Phase 2","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"PHYTONADIONE","company_name":"","drug_phase":"marketed","molecular_target":"Vitamin K epoxide reductase complex subunit 1 (VKORC1)","drug_class":"Vitamin K [EPC]","quality_score":65,"revenue":null,"mechanism":""}],"offLabel":[],"totalMarketed":25,"totalPipeline":2},"trials":{"data":[{"nct_id":"NCT04834843","title":"Temporal Trends of COronary Artery Disease and PEripheral Artery Disease (COPE) in Korea","phase":"","overall_status":"COMPLETED","enrollment_count":700000,"lead_sponsor_name":"Wonju Severance Christian Hospital","has_results":false},{"nct_id":"NCT07442500","title":"Drug Coated Balloon vs. Drug-eluting Stent in Patients With Coronary Artery Disease","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":470000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT07249164","title":"Perioperative Dexmedetomidine and 30-Day Outcomes After Adult Cardiac Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":408153,"lead_sponsor_name":"China Medical University Hospital","has_results":false},{"nct_id":"NCT04715594","title":"CONNECT DES Registrty","phase":"","overall_status":"UNKNOWN","enrollment_count":350000,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT04824729","title":"A Study Related to the VOYAGER PAD Trial to Learn More About the Target Population for Xarelto in French Patients","phase":"","overall_status":"COMPLETED","enrollment_count":227613,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT04778969","title":"Kor PCI - CAD Patients Treated With PCI: Analysis of the Korean Nationwide Health Insurance Database","phase":"","overall_status":"UNKNOWN","enrollment_count":200000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT05050877","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention II","phase":"","overall_status":"COMPLETED","enrollment_count":184855,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT06338956","title":"Optimal Attained LDL-Cholesterol Levels in Patients Who Achieved ≥50% LDL Reduction After PCI","phase":"","overall_status":"COMPLETED","enrollment_count":135877,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06241833","title":"Emulation of Randomized Clinical Trial in Cardiovascular Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":118420,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05337319","title":"Prospective Registry of the Current Status of Care for Patients With Coronary Artery Disease","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Beijing Anzhen Hospital","has_results":false},{"nct_id":"NCT07068490","title":"Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.","phase":"","overall_status":"RECRUITING","enrollment_count":100000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT06512493","title":"South East (Zuid Oost) Netherlands Heart Registry","phase":"","overall_status":"RECRUITING","enrollment_count":99999,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT04407936","title":"Risk Factors and Prognosis of Adverse Cardiovascular and Kidney Events After Coronary Intervention","phase":"","overall_status":"COMPLETED","enrollment_count":88938,"lead_sponsor_name":"Guangdong Provincial People's Hospital","has_results":false},{"nct_id":"NCT04597489","title":"Fractional FLOw Reserve In Cardiovascular DiseAses","phase":"","overall_status":"COMPLETED","enrollment_count":64045,"lead_sponsor_name":"LinkCare GmbH","has_results":false},{"nct_id":"NCT02850588","title":"SVS VQI TransCarotid Revascularization Surveillance Project","phase":"","overall_status":"RECRUITING","enrollment_count":60000,"lead_sponsor_name":"Society for Vascular Surgery Patient Safety Organization","has_results":false},{"nct_id":"NCT03909022","title":"Assessing Best Medical Treatment Patterns of Patients With Symptomatic Peripheral Arterial Occlusive Disease in Germany","phase":"","overall_status":"UNKNOWN","enrollment_count":60000,"lead_sponsor_name":"Universitätsklinikum Hamburg-Eppendorf","has_results":false},{"nct_id":"NCT06595342","title":"A Prospective Cohort of Patients With Cervical/Intracranial Arteries Stenosis in China","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60000,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT03258983","title":"Alpha-linolenic Acid and the Risk of ASCVD","phase":"","overall_status":"COMPLETED","enrollment_count":57053,"lead_sponsor_name":"Aalborg University Hospital","has_results":false},{"nct_id":"NCT04196712","title":"Essen Coronary Artery Disease Registry","phase":"","overall_status":"RECRUITING","enrollment_count":55000,"lead_sponsor_name":"University Hospital, Essen","has_results":false},{"nct_id":"NCT04691037","title":"CCTA Improves Clinical Management of Stable Chest Pain","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tianjin Chest Hospital","has_results":false},{"nct_id":"NCT07063147","title":"TTE Improves Clinical Management of Stable Chest Pain","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"Tianjin Chest Hospital","has_results":false},{"nct_id":"NCT02425345","title":"Women's Health Initiative Strong and Healthy Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":49331,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT06488352","title":"Enhancing Care Study in Patients After CABG","phase":"","overall_status":"RECRUITING","enrollment_count":40000,"lead_sponsor_name":"Chinese Academy of Medical Sciences, Fuwai Hospital","has_results":false},{"nct_id":"NCT05051904","title":"A Study Based on Japanese Medical Records That Looks at Bleeding Events in People With Atrial Fibrillation and Coronary Artery Disease Who Start Taking Either Dabigatran, Rivaroxaban, or Warfarin","phase":"","overall_status":"COMPLETED","enrollment_count":39357,"lead_sponsor_name":"Boehringer Ingelheim","has_results":true},{"nct_id":"NCT05706688","title":"Effect of Regional Versus General Anesthesia on Thirty-day Outcomes Following Carotid Endarterectomy: a Matched-pairs Cohort Study.","phase":"","overall_status":"COMPLETED","enrollment_count":37204,"lead_sponsor_name":"University of Virginia","has_results":false},{"nct_id":"NCT04279496","title":"Coronary CT Angiography Evaluation for Clinical Outcomes: An International Multicenter Registry","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":35000,"lead_sponsor_name":"Cleerly, Inc.","has_results":false},{"nct_id":"NCT07480512","title":"Causation And Prognosis Analyses of Coronary Artery Diseases: A Longitudinal Cohort Study","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT06459934","title":"Clinical Outcomes of Cardiovascular Disease","phase":"","overall_status":"RECRUITING","enrollment_count":30000,"lead_sponsor_name":"Xinjiang Medical University","has_results":false},{"nct_id":"NCT06736626","title":"The xDAPT External Validation Study","phase":"","overall_status":"COMPLETED","enrollment_count":30000,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT06881901","title":"Antiplatelet Strategy for CCS Patients Undergoing CABG","phase":"","overall_status":"COMPLETED","enrollment_count":29898,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT04054440","title":"Outpatient Office Based Endovascular Procedures","phase":"","overall_status":"COMPLETED","enrollment_count":26000,"lead_sponsor_name":"Methodist Health System","has_results":false},{"nct_id":"NCT06001073","title":"Prognosis Prediction System of Patients With Cardiovascular and Cerebrovascular Diseases Based on Multi-omics","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"First Affiliated Hospital Xi'an Jiaotong University","has_results":false},{"nct_id":"NCT03781492","title":"Stable Angina Management and Treatment","phase":"","overall_status":"RECRUITING","enrollment_count":25000,"lead_sponsor_name":"Silesian Centre for Heart Diseases","has_results":false},{"nct_id":"NCT04844944","title":"The Helios Heart Registry: A Standardized Registry for Patients With Specific Cardiac Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":24000,"lead_sponsor_name":"Helios Health Institute GmbH","has_results":false},{"nct_id":"NCT06933745","title":"Ultrasound Assessment of Atherosclerotic Plaque Burden and Cardiovascular Risk: A 10-Year Prospective Study","phase":"","overall_status":"COMPLETED","enrollment_count":21029,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT06376851","title":"AI DErived Plaque Quantification: CCTA and AI-QCPA for Determining Effective CAD Management","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"HeartFlow, Inc.","has_results":false},{"nct_id":"NCT07202754","title":"Procedural Complications and Long-Term Mortality in Complex Coronary Interventions","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Istanbul Mehmet Akif Ersoy Educational and Training Hospital","has_results":false},{"nct_id":"NCT06338761","title":"Switching to E-cigarette After PCI","phase":"","overall_status":"COMPLETED","enrollment_count":17973,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT03507205","title":"Korean Nationwide Multicenter Pooled Registry of Drug-Eluting Stents","phase":"","overall_status":"COMPLETED","enrollment_count":17286,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03338335","title":"Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration","phase":"","overall_status":"UNKNOWN","enrollment_count":16000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT01813435","title":"GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":15991,"lead_sponsor_name":"ECRI bv","has_results":true},{"nct_id":"NCT06565793","title":"A MAajor RAdiation-based PCI Study in STEMI and NSTEMI","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":15630,"lead_sponsor_name":"Centre Cardiologique du Nord","has_results":false},{"nct_id":"NCT07482228","title":"Long-term Clinical Outcomes After Retinal Artery Occlusion","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Chonnam National University Hospital","has_results":false},{"nct_id":"NCT05624905","title":"Prospective Pecutaneous Coronary Intervention Registry","phase":"","overall_status":"RECRUITING","enrollment_count":15000,"lead_sponsor_name":"Samsung Medical Center","has_results":false},{"nct_id":"NCT05888168","title":"Predictors of Postoperative Atrial Fibrillation After CABG","phase":"","overall_status":"UNKNOWN","enrollment_count":15000,"lead_sponsor_name":"Kun Hua","has_results":false},{"nct_id":"NCT01732822","title":"A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":13885,"lead_sponsor_name":"AstraZeneca","has_results":true},{"nct_id":"NCT04734028","title":"PTRG-DES Consortium","phase":"","overall_status":"COMPLETED","enrollment_count":13160,"lead_sponsor_name":"Gyeongsang National University Hospital","has_results":false},{"nct_id":"NCT06855394","title":"Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":13000,"lead_sponsor_name":"University of Florida","has_results":false},{"nct_id":"NCT06558474","title":"Optimization of Percutaenous Coronary Intervention With Liberal Use of Post-dilatation","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Cathreine BV","has_results":false},{"nct_id":"NCT04564794","title":"Prognostic Value of Cardial Stress Perfusion Imaging","phase":"","overall_status":"COMPLETED","enrollment_count":11952,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}